Biotech Values

[DewDiligence]

Prolia/Xgeva (denosumab) notes from AMGN’s 1Q11 CC:

• Worldwide 1Q11 sales were $27M for Prolia and $42M for Xgeva. (Did anyone here expect Xgeva to outsell Prolia despite the later approval? I certainly didn’t.)

• 20% of Prolia and 33% of Xgeva use is in the first-line setting.

• Prolia scripts increased by 50% in Mar 2011 vs Feb 2011.

• 2/3 of Prolia prescriptions come from GP’s and 1/3 from specialists.

• 50% of Xgeva use is in breast cancer and most of the rest is in prostate cancer.

• Among the prostate use of Xgeva, 75% is in oncology clinics and 25% in urology clinics.